News | January 21, 2022
Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
Biocon has reported consolidated financial results for the period ended December 31, 2021
Biocon has reported consolidated financial results for the period ended December 31, 2021
Ram’s appointment follows the launch of the CDI India division in October 2021.
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
Prior to IHH, Anurag held senior leadership roles in Fortis Healthcare and Manipal Health Enterprises.
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
Subscribe To Our Newsletter & Stay Updated
